What can clonal evolution in chronic lymphocytic leukemia (CLL) tell us about outcomes?
Overview of research in Waldenström’s macroglobulinemia therapies
The utility of measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)
Gert J. Ossenkoppele
Clinical implications of persisting preleukemic clones in remission in acute myeloid leukemia (AML)
The progress of CLL research: towards targeted therapy